CCNE1 Gain Defines a Therapy-Refractory Gastric Cancer Subtype

Unambiguous delineation of a CCNE1-driven gastric cancer subtype and its immune milieu

The aim was to characterize tumors with CCNE1 gain, defined by amplification or Cyclin E1 overexpression, relative to epithelial and mesenchymal states across clinicopathologic features, outcomes, and immune contexture.

The analysis encompassed clinicopathologic attributes, survival, treatment responses, and immune phenotype.

• This report synthesizes findings from 1,273 gastric cancer patients drawn from six independent cohorts (ZSHS, TCGA, ACRG, SMC, MSKCC, and ZSHS NGS).
• Tumors were stratified into CCNE1 gain, epithelial, or mesenchymal subtypes using integrated data from protein expression, copy-number analyses, and transcript levels.

• Despite preserved epithelial morphology, CCNE1 gain tumors demonstrated heightened proliferative activity and more frequent nerve and venous invasion compared with other subtypes.
• E-cadherin positivity was retained in CCNE1 gain lesions, indicating that the epithelial phenotype persisted even with aggressive behavior.
• Across the studied cohorts, CCNE1 gain was linked to poorer prognosis and diminished response to multiple therapeutic modalities, including adjuvant chemotherapy, HER2-targeted therapy, anti-angiogenic therapy, and anti-PD-1 immunotherapy, independent of the broader epithelial-mesenchymal classification.

• The immune landscape of CCNE1 gain tumors was characterized as immune-desert, with notably reduced lymphocyte infiltration.
• Functional attributes included impaired cytotoxic activity and a shift toward M2 macrophage polarization.
• Cytokine milieu and signaling patterns favored elevated transforming growth factor-beta (TGF-β), aligning with an immune-suppressive ecosystem that may limit anti-tumor immunity.

It identifies a subset comprising more than 10% of gastric cancer patients in the pooled datasets who exhibit a paradox of preserved epithelial morphology alongside aggressive proliferation, invasion, and immune evasion.

However, the source does not provide quantitative treatment response rates or outcome metrics beyond qualitative statements of reduced responsiveness and prognosis.

• CCNE1 gain defines a distinct, clinically actionable gastric cancer subset that transcends the conventional epithelial-mesenchymal (EM) axis.
• The observed pattern—preserved epithelial markers with enhanced aggressive behavior and an immune-desert, myeloid-dominated microenvironment—suggests a decoupling of surface phenotype from invasive and immunologic dynamics in this subgroup.
• Therapeutic implications inferred from the data indicate broad resistance signatures across dominant treatment modalities, including chemotherapeutic, targeted, anti-angiogenic, and PD-1–axis interventions, irrespective of EM classification.

• The analysis leverages multi-cohort integration, combining protein-level, copy-number, and transcript-level data to assign CCNE1 gain status and to parse epithelial versus mesenchymal contexts.
• Survival and response in relation to CCNE1 gain were assessed across the included cohorts, reinforcing the consistency of key associations (poor prognosis, reduced therapy responsiveness) with the CCNE1 gain phenotype, beyond EM categorization.

• The provided content does not specify numerical survival outcomes, effect sizes, or statistical metrics for the associations described.
• Details on potential cohort-specific heterogeneity, upstream drivers of CCNE1 gain, or the mechanistic underpinnings linking CCNE1 amplification to immune-desert features are not elaborated in the source text.
• The note about access to supplementary data or materials is present, but some data are restricted by institutional access; opportunities for external validation or data sharing are limited by stated access conditions.
• It remains unclear whether the CCNE1 gain subgroup has distinct responses to particular therapeutic regimens when controlled for other molecular features or EM status.

• Recognition of CCNE1 gain as a distinct, therapy-refractory subtype could inform future stratification in gastric cancer research and clinical trial design, focusing on mechanisms of immune exclusion and cell cycle–driven proliferation.
• Open questions include the precise prevalence of CCNE1 gain across broader populations, the reproducibility of the immune-desert phenotype in independent datasets, and the identification of potential vulnerabilities beyond current standard therapies.

Quantitative depth and mechanistic detail are limited in the provided content, and explicit numerical outcomes are not included.

• The narrative consistently emphasizes the CCNE1 gain–associated immune-desert microenvironment and therapy resistance as reported in the source.